Itraconazole to Prevent Fungal Infections in Chronic Granulomatous Disease
In chronic granulomatous disease of childhood, killing of microorganisms is impaired because of defects in the production of hydrogen peroxide. In this controlled study, 39 patients were treated in alternate years with either itraconazole or placebo, once per day. There were seven serious infections...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2003-06, Vol.348 (24), p.2416-2422 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2422 |
|---|---|
| container_issue | 24 |
| container_start_page | 2416 |
| container_title | The New England journal of medicine |
| container_volume | 348 |
| creator | Gallin, John I Alling, David W Malech, Harry L Wesley, Robert Koziol, Deloris Marciano, Beatriz Eisenstein, Eli M Turner, Maria L DeCarlo, Ellen S Starling, Judith M Holland, Steven M |
| description | In chronic granulomatous disease of childhood, killing of microorganisms is impaired because of defects in the production of hydrogen peroxide. In this controlled study, 39 patients were treated in alternate years with either itraconazole or placebo, once per day. There were seven serious infections during treatment with placebo, and only one during treatment with itraconazole.
Chronic granulomatous disease of childhood is a rare group of inherited disorders of phagocytic cells characterized clinically by recurrent life-threatening infections and excessive granuloma formation.
1
Phagocyte migration and phagocytosis are normal, but killing of microorganisms is impaired because of defective production of hydrogen peroxide and related products of oxygen metabolism. A variety of biochemical defects lead to the disorder.
The current mortality rate is 2 to 5 percent per year.
2
In the absence of prophylaxis with antibiotics or interferon gamma, patients with chronic granulomatous disease have severe infections due to catalase-positive bacteria and fungi about once a year. Prophylaxis with . . . |
| doi_str_mv | 10.1056/NEJMoa021931 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_223932380</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>346426241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c568t-a51ba5fd6fca4d5406622a9243abb0478c8d132ef0610dcb82bd8aba5ddd1b943</originalsourceid><addsrcrecordid>eNptkD1PwzAQhi0EoqWwMaMIwUbAX0mcEZW2tCofA8zRxXYgVWIXO0GCX4-rVoKBW2557n1PD0KnBF8TnKQ3j5PFgwVMSc7IHhqShLGYc5zuoyHGVMQ8y9kAHXm_wmEIzw_RgFCBKabZEC3mnQNpDXzbRkedjZ6d_tSmi6a9eYMmmptKy662xke1icbvzppaRjMHpm9sC53tfXRXew1eH6ODChqvT3Z7hF6nk5fxfbx8ms3Ht8tYJqnoYkhICUml0koCV0n4NKUUcsoZlCXmmZBCEUZ1hVOClSwFLZWAcKKUImXO2Qidb3PXzn702nfFyvbOhMqCUpYzygQO0NUWks5673RVrF3dgvsqCC423oq_3gJ-tsvsy1arX3gnKgCXOwC8hKYKAmTtfzkusjTjm96LLde2vjB61f7f9wOP1ICa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223932380</pqid></control><display><type>article</type><title>Itraconazole to Prevent Fungal Infections in Chronic Granulomatous Disease</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Gallin, John I ; Alling, David W ; Malech, Harry L ; Wesley, Robert ; Koziol, Deloris ; Marciano, Beatriz ; Eisenstein, Eli M ; Turner, Maria L ; DeCarlo, Ellen S ; Starling, Judith M ; Holland, Steven M</creator><creatorcontrib>Gallin, John I ; Alling, David W ; Malech, Harry L ; Wesley, Robert ; Koziol, Deloris ; Marciano, Beatriz ; Eisenstein, Eli M ; Turner, Maria L ; DeCarlo, Ellen S ; Starling, Judith M ; Holland, Steven M</creatorcontrib><description>In chronic granulomatous disease of childhood, killing of microorganisms is impaired because of defects in the production of hydrogen peroxide. In this controlled study, 39 patients were treated in alternate years with either itraconazole or placebo, once per day. There were seven serious infections during treatment with placebo, and only one during treatment with itraconazole.
Chronic granulomatous disease of childhood is a rare group of inherited disorders of phagocytic cells characterized clinically by recurrent life-threatening infections and excessive granuloma formation.
1
Phagocyte migration and phagocytosis are normal, but killing of microorganisms is impaired because of defective production of hydrogen peroxide and related products of oxygen metabolism. A variety of biochemical defects lead to the disorder.
The current mortality rate is 2 to 5 percent per year.
2
In the absence of prophylaxis with antibiotics or interferon gamma, patients with chronic granulomatous disease have severe infections due to catalase-positive bacteria and fungi about once a year. Prophylaxis with . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa021931</identifier><identifier>PMID: 12802027</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Adolescent ; Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antifungal agents ; Antifungal Agents - adverse effects ; Antifungal Agents - blood ; Antifungal Agents - therapeutic use ; Bacterial infections ; Biological and medical sciences ; Child ; Child, Preschool ; Cross-Over Studies ; Double-Blind Method ; Female ; Granulomatous Disease, Chronic - complications ; Granulomatous Disease, Chronic - drug therapy ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Interferon ; Itraconazole - adverse effects ; Itraconazole - blood ; Itraconazole - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Mortality ; Mycoses - etiology ; Mycoses - prevention & control ; Patient Compliance ; Pharmacology. Drug treatments ; Rare Diseases - drug therapy ; Stem cells ; Transplants & implants</subject><ispartof>The New England journal of medicine, 2003-06, Vol.348 (24), p.2416-2422</ispartof><rights>Copyright © 2003 Massachusetts Medical Society. All rights reserved.</rights><rights>2003 INIST-CNRS</rights><rights>Copyright 2003 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c568t-a51ba5fd6fca4d5406622a9243abb0478c8d132ef0610dcb82bd8aba5ddd1b943</citedby><cites>FETCH-LOGICAL-c568t-a51ba5fd6fca4d5406622a9243abb0478c8d132ef0610dcb82bd8aba5ddd1b943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa021931$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa021931$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14876740$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12802027$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gallin, John I</creatorcontrib><creatorcontrib>Alling, David W</creatorcontrib><creatorcontrib>Malech, Harry L</creatorcontrib><creatorcontrib>Wesley, Robert</creatorcontrib><creatorcontrib>Koziol, Deloris</creatorcontrib><creatorcontrib>Marciano, Beatriz</creatorcontrib><creatorcontrib>Eisenstein, Eli M</creatorcontrib><creatorcontrib>Turner, Maria L</creatorcontrib><creatorcontrib>DeCarlo, Ellen S</creatorcontrib><creatorcontrib>Starling, Judith M</creatorcontrib><creatorcontrib>Holland, Steven M</creatorcontrib><title>Itraconazole to Prevent Fungal Infections in Chronic Granulomatous Disease</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In chronic granulomatous disease of childhood, killing of microorganisms is impaired because of defects in the production of hydrogen peroxide. In this controlled study, 39 patients were treated in alternate years with either itraconazole or placebo, once per day. There were seven serious infections during treatment with placebo, and only one during treatment with itraconazole.
Chronic granulomatous disease of childhood is a rare group of inherited disorders of phagocytic cells characterized clinically by recurrent life-threatening infections and excessive granuloma formation.
1
Phagocyte migration and phagocytosis are normal, but killing of microorganisms is impaired because of defective production of hydrogen peroxide and related products of oxygen metabolism. A variety of biochemical defects lead to the disorder.
The current mortality rate is 2 to 5 percent per year.
2
In the absence of prophylaxis with antibiotics or interferon gamma, patients with chronic granulomatous disease have severe infections due to catalase-positive bacteria and fungi about once a year. Prophylaxis with . . .</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antifungal agents</subject><subject>Antifungal Agents - adverse effects</subject><subject>Antifungal Agents - blood</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Bacterial infections</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cross-Over Studies</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Granulomatous Disease, Chronic - complications</subject><subject>Granulomatous Disease, Chronic - drug therapy</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Interferon</subject><subject>Itraconazole - adverse effects</subject><subject>Itraconazole - blood</subject><subject>Itraconazole - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Mycoses - etiology</subject><subject>Mycoses - prevention & control</subject><subject>Patient Compliance</subject><subject>Pharmacology. Drug treatments</subject><subject>Rare Diseases - drug therapy</subject><subject>Stem cells</subject><subject>Transplants & implants</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkD1PwzAQhi0EoqWwMaMIwUbAX0mcEZW2tCofA8zRxXYgVWIXO0GCX4-rVoKBW2557n1PD0KnBF8TnKQ3j5PFgwVMSc7IHhqShLGYc5zuoyHGVMQ8y9kAHXm_wmEIzw_RgFCBKabZEC3mnQNpDXzbRkedjZ6d_tSmi6a9eYMmmptKy662xke1icbvzppaRjMHpm9sC53tfXRXew1eH6ODChqvT3Z7hF6nk5fxfbx8ms3Ht8tYJqnoYkhICUml0koCV0n4NKUUcsoZlCXmmZBCEUZ1hVOClSwFLZWAcKKUImXO2Qidb3PXzn702nfFyvbOhMqCUpYzygQO0NUWks5673RVrF3dgvsqCC423oq_3gJ-tsvsy1arX3gnKgCXOwC8hKYKAmTtfzkusjTjm96LLde2vjB61f7f9wOP1ICa</recordid><startdate>20030612</startdate><enddate>20030612</enddate><creator>Gallin, John I</creator><creator>Alling, David W</creator><creator>Malech, Harry L</creator><creator>Wesley, Robert</creator><creator>Koziol, Deloris</creator><creator>Marciano, Beatriz</creator><creator>Eisenstein, Eli M</creator><creator>Turner, Maria L</creator><creator>DeCarlo, Ellen S</creator><creator>Starling, Judith M</creator><creator>Holland, Steven M</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20030612</creationdate><title>Itraconazole to Prevent Fungal Infections in Chronic Granulomatous Disease</title><author>Gallin, John I ; Alling, David W ; Malech, Harry L ; Wesley, Robert ; Koziol, Deloris ; Marciano, Beatriz ; Eisenstein, Eli M ; Turner, Maria L ; DeCarlo, Ellen S ; Starling, Judith M ; Holland, Steven M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c568t-a51ba5fd6fca4d5406622a9243abb0478c8d132ef0610dcb82bd8aba5ddd1b943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antifungal agents</topic><topic>Antifungal Agents - adverse effects</topic><topic>Antifungal Agents - blood</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Bacterial infections</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cross-Over Studies</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Granulomatous Disease, Chronic - complications</topic><topic>Granulomatous Disease, Chronic - drug therapy</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Interferon</topic><topic>Itraconazole - adverse effects</topic><topic>Itraconazole - blood</topic><topic>Itraconazole - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Mycoses - etiology</topic><topic>Mycoses - prevention & control</topic><topic>Patient Compliance</topic><topic>Pharmacology. Drug treatments</topic><topic>Rare Diseases - drug therapy</topic><topic>Stem cells</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gallin, John I</creatorcontrib><creatorcontrib>Alling, David W</creatorcontrib><creatorcontrib>Malech, Harry L</creatorcontrib><creatorcontrib>Wesley, Robert</creatorcontrib><creatorcontrib>Koziol, Deloris</creatorcontrib><creatorcontrib>Marciano, Beatriz</creatorcontrib><creatorcontrib>Eisenstein, Eli M</creatorcontrib><creatorcontrib>Turner, Maria L</creatorcontrib><creatorcontrib>DeCarlo, Ellen S</creatorcontrib><creatorcontrib>Starling, Judith M</creatorcontrib><creatorcontrib>Holland, Steven M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gallin, John I</au><au>Alling, David W</au><au>Malech, Harry L</au><au>Wesley, Robert</au><au>Koziol, Deloris</au><au>Marciano, Beatriz</au><au>Eisenstein, Eli M</au><au>Turner, Maria L</au><au>DeCarlo, Ellen S</au><au>Starling, Judith M</au><au>Holland, Steven M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Itraconazole to Prevent Fungal Infections in Chronic Granulomatous Disease</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2003-06-12</date><risdate>2003</risdate><volume>348</volume><issue>24</issue><spage>2416</spage><epage>2422</epage><pages>2416-2422</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>In chronic granulomatous disease of childhood, killing of microorganisms is impaired because of defects in the production of hydrogen peroxide. In this controlled study, 39 patients were treated in alternate years with either itraconazole or placebo, once per day. There were seven serious infections during treatment with placebo, and only one during treatment with itraconazole.
Chronic granulomatous disease of childhood is a rare group of inherited disorders of phagocytic cells characterized clinically by recurrent life-threatening infections and excessive granuloma formation.
1
Phagocyte migration and phagocytosis are normal, but killing of microorganisms is impaired because of defective production of hydrogen peroxide and related products of oxygen metabolism. A variety of biochemical defects lead to the disorder.
The current mortality rate is 2 to 5 percent per year.
2
In the absence of prophylaxis with antibiotics or interferon gamma, patients with chronic granulomatous disease have severe infections due to catalase-positive bacteria and fungi about once a year. Prophylaxis with . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>12802027</pmid><doi>10.1056/NEJMoa021931</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2003-06, Vol.348 (24), p.2416-2422 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_223932380 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Adolescent Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antifungal agents Antifungal Agents - adverse effects Antifungal Agents - blood Antifungal Agents - therapeutic use Bacterial infections Biological and medical sciences Child Child, Preschool Cross-Over Studies Double-Blind Method Female Granulomatous Disease, Chronic - complications Granulomatous Disease, Chronic - drug therapy Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Interferon Itraconazole - adverse effects Itraconazole - blood Itraconazole - therapeutic use Male Medical sciences Middle Aged Mortality Mycoses - etiology Mycoses - prevention & control Patient Compliance Pharmacology. Drug treatments Rare Diseases - drug therapy Stem cells Transplants & implants |
| title | Itraconazole to Prevent Fungal Infections in Chronic Granulomatous Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T04%3A14%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Itraconazole%20to%20Prevent%20Fungal%20Infections%20in%20Chronic%20Granulomatous%20Disease&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Gallin,%20John%20I&rft.date=2003-06-12&rft.volume=348&rft.issue=24&rft.spage=2416&rft.epage=2422&rft.pages=2416-2422&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa021931&rft_dat=%3Cproquest_cross%3E346426241%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223932380&rft_id=info:pmid/12802027&rfr_iscdi=true |